Patients with metastatic solid cancer (gastric cancer, colorectal cancer and breast cancer) scheduled for first line chemotherapy (including molecular targeted drug and immune checkpoint inhibitor)
Conditions
Interventions
None listed
Sponsors
Kobe City Medical Center General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with metastatic solid cancer (gastric cancer, colorectal cancer, breast cancer) 2) Patients who are scheduled for first-line chemotherapy (including molecular targeted drug and immune checkpoint inhibitor) 3) Patients who are going to do chemotherapy at the outpatient chemotherapy unit 4) Patient with ECOG Performance Status of 0 to 2. 5) Patients who are expected to have a prognosis of six months or more 6) Written informed consent, with the understanding that the patient may withdraw consent at any time without prejudice
Exclusion criteria
Exclusion criteria: 1) Patients with serious complications 2) Patients who have clinically problematic mental illness 3) Patients judged inappropriate for enrolment by physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EQ-5D-5L | — |
Secondary
| Measure | Time frame |
|---|---|
| Global Health Status scale in EORTC QLQ-C30 EORTC QLQ-C30(five functional scales and three multi-item symptom scales) EORTC QLQ-CIPN20 Overall survival from the registration date Association between clinicopatholigical factors and HRQOL Association between sociodemographic factors and HRQOL Association between visiting emergency room and HRQOL Association between visiting palliative care unit and HRQOL Association between symptom monitoring via Patient Portal Site and HRQOL | — |
Countries
Japan
Contacts
Public ContactYuichiro Kikawa
Kobe City Medical Center General Hospital Department of Breast Surgery
Outcome results
None listed